Login to Your Account

Can-Fite Closes $12M Round; CF101 Phase II Trials Planned

By Rachelle H.B. Fishman

Wednesday, June 18, 2003
ZICHRON YA'AKOV, Israel - Privately held Can-Fite BioPharma Ltd., focused on targeted treatments for cancer and inflammatory diseases, completed a financing round nearing $12 million, at a post-money valuation of $22 million. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription